Induction therapy with thymoglobulin or interleukin-2 receptor antagonist for Chinese recipients of living donor renal transplantation: a retrospective study

[1]  H. Yin,et al.  A Cost-effectiveness Analysis of Rabbit Antithymocyte Globulin Versus Antithymocyte Globulin-fresenius as Induction Therapy for Patients With Kidney Transplantation From Donation After Cardiac Death in China. , 2018, Clinical therapeutics.

[2]  Rajan K. Patel,et al.  Renal association clinical practice guideline in post-operative care in the kidney transplant recipient , 2017, BMC Nephrology.

[3]  Jianyong Wu,et al.  Basiliximab versus rabbit antithymocyte globulin as induction therapy for living-related renal transplantation: a single-center experience , 2016, International Urology and Nephrology.

[4]  T. Fehr,et al.  Association of Kidney Graft Loss With De Novo Produced Donor-Specific and Non-Donor-Specific HLA Antibodies Detected by Single Antigen Testing , 2015, Transplantation.

[5]  Song Zhang,et al.  Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[6]  M. F. D. de Carvalho,et al.  Different induction therapies for kidney transplantation with living donor. , 2015, Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia.

[7]  J. Boletis,et al.  Incidence and Clinical Significance of De Novo Donor Specific Antibodies after Kidney Transplantation , 2013, Clinical & developmental immunology.

[8]  Gang Huang,et al.  Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function. , 2013, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[9]  D. Brennan,et al.  Selection of induction therapy in kidney transplantation , 2013, Transplant international : official journal of the European Society for Organ Transplantation.

[10]  Rubin Zhang.  Modern Immunosuppressive Therapy in Kidney Transplantation , 2013 .

[11]  C. Haisch,et al.  Incidence and Impact of De Novo Donor-Specific Alloantibody in Primary Renal Allografts , 2013, Transplantation.

[12]  A. Gaber,et al.  Antithymocyte Globulin Induction in Living Donor Renal Transplant Recipients: Final Report of the TAILOR Registry , 2012, Transplantation.

[13]  J. Cooper,et al.  Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts. , 2011, Clinical transplants.

[14]  Junchao Cai,et al.  Induction Immunosuppression Improves Long-Term Graft and Patient Outcome in Organ Transplantation: An Analysis of United Network for Organ Sharing Registry Data , 2010, Transplantation.

[15]  Ethan M Balk,et al.  KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. , 2010, Kidney international.

[16]  F. Luan,et al.  Clinical and Economic Outcomes of Rabbit Antithymocyte Globulin Induction in Adults Who Received Kidney Transplants from Living Unrelated Donors and Received Cyclosporine‐Based Immunosuppression , 2009, Pharmacotherapy.

[17]  A. Langnas,et al.  Randomized Trial of Single-Dose Versus Divided-Dose Rabbit Anti-Thymocyte Globulin Induction in Renal Transplantation: An Interim Report , 2008, Transplantation.

[18]  Alan B Leichtman,et al.  Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQITM) conference. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[19]  D. Brennan,et al.  Rabbit antithymocyte globulin versus basiliximab in renal transplantation. , 2006, The New England journal of medicine.

[20]  J. Gore,et al.  Obesity and Outcome Following Renal Transplantation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  J. Squifflet,et al.  A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients1 , 2003, Transplantation.

[22]  D. Dunn,et al.  Immunologic and nonimmunologic factors: different risks for cadaver and living donor transplantation. , 2000, Transplantation.

[23]  Robert Kerchner,et al.  Interim Report , 1996 .